National Trends in the Antipsychotic Treatment of Psychiatric Outpatients With Anxiety Disorders

被引:69
作者
Comer, Jonathan S. [1 ]
Mojtabai, Ramin
Olfson, Mark
机构
[1] Boston Univ, Dept Psychol, Ctr Anxiety & Related Disorders, Boston, MA 02215 USA
基金
美国国家卫生研究院; 美国医疗保健研究与质量局;
关键词
OBSESSIVE-COMPULSIVE DISORDER; DOUBLE-BLIND; OLANZAPINE; MEDICATIONS; RISPERIDONE; CHILDREN; RISK; AUGMENTATION; ADOLESCENTS; MONOTHERAPY;
D O I
10.1176/appi.ajp.2011.11010087
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The purpose of the present study was to examine patterns and recent trends in the antipsychotic medication treatment of anxiety disorders among visits to office-based psychiatrists in the United States. Method: Annual data from the 1996-2007 National Ambulatory Medical Care Survey were analyzed to examine the patterns and trends in antipsychotic medication treatment within a nationally representative sample of 4,166 visits to office-based psychiatrists in which an anxiety disorder was diagnosed. Results: Across the 12-year period, antipsychotic prescriptions in visits for anxiety disorders increased from 10.6% (1996-1999) to 21.3% (2004-2007). Over the study period, the largest increase in antipsychotic prescribing occurred among new patient visits. Antipsychotic prescribing also significantly increased among privately insured visits and visits in which neither antidepressants nor sedative/hypnotics were prescribed. Among the common anxiety disorder diagnoses, the largest increase in antipsychotic medication treatment was observed in visits for panic disorder. Antipsychotic prescribing rose from 6.9% (1996-1999) to 14.5% (20042007) among visits for anxiety disorders in which there were no co-occurring diagnoses with an indication approved by the Food and Drug Administration for antipsychotic medications. Conclusions: Although little is known about their effectiveness for anxiety disorders, antipsychotic medications are becoming increasingly prescribed to psychiatric outpatients with these disorders.
引用
收藏
页码:1057 / 1065
页数:9
相关论文
共 40 条
[1]   Increasing off-label use of antipsychotic medications in the United States, 1995-2008 [J].
Alexander, G. C. ;
Gallagher, S. A. ;
Mascola, A. ;
Moloney, R. M. ;
Stafford, R. S. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (02) :177-184
[2]   Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study [J].
Bandelow, Borwin ;
Chouinard, Guy ;
Bobes, Julio ;
Ahokas, Antti ;
Eggens, Ivan ;
Liu, Sherry ;
Eriksson, Hans .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 (03) :305-320
[3]  
Barlow D.H., 2001, CLIN HDB PSYCHOL DIS, V3
[4]   Efficacy of olanzapine in social anxiety disorder: a pilot study [J].
Barnett, SD ;
Kramer, ML ;
Casat, CD ;
Connor, KM ;
Davidson, JRT .
JOURNAL OF PSYCHOPHARMACOLOGY, 2002, 16 (04) :365-368
[5]   Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants [J].
Berman, Robert M. ;
Fava, Maurizio ;
Thase, Michael E. ;
Trivedi, Madhukar H. ;
Swanink, Rene ;
McQuade, Robert D. ;
Carson, William H. ;
Adson, David ;
Taylor, Leslie ;
Hazel, James ;
Marcus, Ronald N. .
CNS SPECTRUMS, 2009, 14 (04) :197-206
[6]  
Black N, 1999, J Health Serv Res Policy, V4, P236
[7]   Generalizability of clinical trial results for major depression to community samples: Results from the National Epidemiologic Survey on Alcohol and Related Conditions [J].
Blanco, Carlos ;
Olfson, Mark ;
Goodwin, Renee D. ;
Ogburn, Elizabeth ;
Liebowitz, Michael R. ;
Nunes, Edward V. ;
Hasin, Deborah S. .
JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (08) :1276-1280
[8]   Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients [J].
Blin, O ;
Azorin, JM ;
Bouhours, P .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (01) :38-44
[9]   Adjunctive risperidone in generalized anxiety disorder: A double-blind, placebo-controlled study [J].
Brawman-Mintzer, O ;
Knapp, RG ;
Nietert, PJ .
JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (10) :1321-1325
[10]   Olanzapine in the treatment of post-traumatic stress disorder: a pilot study [J].
Butterfield, MI ;
Becker, ME ;
Connor, KM ;
Sutherland, S ;
Churchill, LE ;
Davidson, JRT .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (04) :197-203